The FDA has extended its review timeline for Exelixis’ colorectal cancer program after the company submitted additional safety and efficacy data, pushing the agency’s decision window by three months. The filing change was triggered by the new package of information for Exelixis’ potential treatment of metastatic colorectal cancer. For developers with time-dependent catalysts, review extensions can affect market expectations, investor positioning, and the timing of any subsequent manufacturing or commercialization planning. The decision also highlights how evolving evidence packages continue to play a material role in FDA review cadence for oncology assets nearing decision points.